<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00170287</url>
  </required_header>
  <id_info>
    <org_study_id>CEN_G_CA_3</org_study_id>
    <nct_id>NCT00170287</nct_id>
  </id_info>
  <brief_title>SMS: Substrate Modification Study in Patients Getting an Implantable Cardioverter Defibrillator (ICD)</brief_title>
  <acronym>SMS</acronym>
  <official_title>Substrate Modification Study in Patients Getting an ICD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present standard of care for the management of unstable ventricular tachycardia (VT) in
      the setting of chronic coronary artery disease is the placement of an implantable
      cardioverter defibrillator (ICD) after the initial episode, and radiofrequency ablation
      and/or antiarrhythmic medication in the event of recurrences causing frequent ICD
      interventions.

      The primary purpose of this randomized study is the assessment of recurrences of unstable VT
      in patients who undergo ICD implantation plus substrate ablation after the initial episode
      compared to patients who only undergo ICD implantation. Thus the primary purpose is an
      improvement in the quality of life. A decrease in mortality is not a primary purpose of this
      study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the first documented recurrence of any sustained VT/ventricular fibrillation (VF) during the follow-up period</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All appropriate ICD therapies (number of shocks, number of antitachycardia pacing therapies)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital readmissions due to a cardiac indication</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe clinical events</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Tachycardia, Ventricular</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ICD Therapy plus VT-Ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ICD Therapy only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ICD Ablation plus VT-ablation</intervention_name>
    <description>ICD-Therapy for the treatment of unstable VT´s plus catheter ablation for substrate modification</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD Therapy</intervention_name>
    <description>ICD Therapy for the Treatment of unstable VT´s</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Coronary artery disease documented by coronary angiography. For the purpose of this
             study, coronary artery disease will be defined as the presence of a 50% or more
             diameter stenosis of the left main or of a 75% or more diameter stenosis of the left
             anterior descending, circumflex or right coronary arteries, or the history of a
             surgical or percutaneous revascularization procedure.

          -  Left ventricular ejection fraction &lt; 40% as estimated by echocardiography or contrast
             ventriculography within the previous 30 days.

          -  Clinical unstable VT without reversible factors (acute ischemia or antiarrhythmic
             medications as defined below). Unstable VT can have one of the following clinical
             presentations:

               -  Hypotensive VT without major neurologic dysfunction;

               -  Syncope; or

               -  Cardiac arrest.

        Exclusion Criteria:

          -  Age &lt; 18 years or &gt; 80 years

          -  Protruding left ventricular (LV) thrombus on pre-ablation echocardiogram

          -  Acute myocardial infarction within the preceding 2 months

          -  Class IV New York Heart Association (NYHA) heart failure

          -  Valvular heart disease or mechanical heart valve precluding access to the left
             ventricle

          -  Unstable angina

          -  Cardiac surgery within the past 2 months

          -  Serum creatinine &gt; 220 mmol/L (2.5 mg/dL)

          -  Thrombocytopenia or coagulopathy

          -  Contraindication to heparin

          -  Pregnancy

          -  Acute illness or active systemic infection

          -  Other disease process likely to limit survival to less than 12 months

          -  Significant medical problem that, in the opinion of the principal investigator, would
             preclude enrollment into the study

          -  Participation in another investigational study

          -  Unwillingness to participate or lack of availability for follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Heinz Kuck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allgemeines Krankenhaus St. Georg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skejby Skygehus</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefäßklinik GmbH</name>
      <address>
        <city>Bad Neustadt / Saale</city>
        <zip>97616</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berufsgenossenschaftliche Kliniken Bergmannsheil</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universität</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unstable Ventricular Tachycardia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

